Shamir R. Mehta

Shamir R. Mehta's AcademicInfluence.com Rankings

Shamir R. Mehta

Medical

#2837

World Rank

#3277

Historical Rank

Cardiology

#272

World Rank

#278

Historical Rank

Public Health

#442

World Rank

#456

Historical Rank

Epidemiology

#541

World Rank

#563

Historical Rank

medical Degrees

Shamir R. Mehta

Philosophy

#8130

World Rank

#11453

Historical Rank

Logic

#5161

World Rank

#6536

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Shamir R. Mehta's Degrees

Doctorate Medicine Harvard University

Why Is Shamir R. Mehta Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Shamir R. Mehta's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. (2001) (4531)
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study (2001) (2577)
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial (2011) (1498)
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes (2006) (1314)
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. (2006) (1125)
Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. (2009) (1051)
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. (2006) (855)
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. (2005) (827)
Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial (2004) (811)
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial (2010) (808)
Early versus delayed invasive intervention in acute coronary syndromes. (2009) (781)
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study ☆ (2002) (747)
Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study (2003) (743)
Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. (2005) (643)
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. (2010) (549)
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. (2010) (545)
Ticagrelor with or without Aspirin in High-Risk Patients after PCI. (2019) (539)
Routine early angioplasty after fibrinolysis for acute myocardial infarction. (2009) (433)
Complete Revascularization with Multivessel PCI for Myocardial Infarction. (2019) (399)
Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction. (2001) (393)
The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. (2000) (328)
Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes (2003) (311)
Differences in the management and prognosis of women and men who suffer from acute coronary syndromes. (2005) (292)
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. (2007) (274)
Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. (2012) (248)
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data (2002) (246)
Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups (2002) (245)
Efficacy and Safety of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent: The EVOLVE II Randomized Trial (2015) (217)
Ticagrelor in Patients with Stable Coronary Disease and Diabetes. (2019) (198)
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome (2011) (191)
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. (2008) (182)
Subclinical Atrial Fibrillation in Older Patients (2017) (179)
In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. (1996) (175)
2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. (2017) (166)
Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial (2016) (166)
Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. (2010) (163)
Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. (2005) (155)
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. (2008) (153)
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. (2007) (137)
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. (2008) (137)
The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. (2009) (137)
Complete vs culprit-only revascularization for patients with multivessel disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review and meta-analysis. (2014) (133)
Effect of radial versus femoral access on radiation dose and the importance of procedural volume: a substudy of the multicenter randomized RIVAL trial. (2013) (133)
Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials (2017) (131)
Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. (2010) (128)
Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction (2009) (127)
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial (2019) (126)
Renal function and outcomes in acute coronary syndrome: impact of clopidogrel (2007) (125)
Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials (2005) (125)
Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention: Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation (ASPIRE) Pilot Trial (2005) (118)
Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in NonST-Segment Elevation Acute Coronary Syndromes (2007) (107)
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. (2012) (107)
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. (2013) (104)
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. (2016) (103)
Radial artery access as a predictor of increased radiation exposure during a diagnostic cardiac catheterization procedure. (2011) (100)
Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2. (2005) (97)
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials (2021) (96)
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. (2003) (95)
2019 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Guidelines on the Acute Management of ST-Elevation Myocardial Infarction: Focused Update on Regionalization and Reperfusion. (2019) (92)
Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. (2008) (92)
Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome (2016) (88)
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. (2010) (86)
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina (2001) (83)
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. (2014) (81)
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. (2013) (80)
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. (2009) (79)
Secretory Phospholipase A2-IIA and Cardiovascular Disease (2013) (78)
Radial Versus Femoral Access for Coronary Angiography/Intervention in Women With Acute Coronary Syndromes: Insights From the RIVAL Trial (Radial Vs femorAL access for coronary intervention). (2015) (78)
Procedural volume and outcomes with radial or femoral access for coronary angiography and intervention. (2014) (78)
Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. (2006) (76)
Incidence, predictors, and clinical significance of troponin-I elevation without creatine kinase elevation following percutaneous coronary interventions. (2004) (76)
Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patie (2015) (76)
Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials. (2012) (72)
Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. (2005) (70)
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. (2013) (70)
Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials (2015) (69)
Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis (2000) (69)
Ticagrelor With or Without Aspirin After Complex PCI (2020) (66)
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. (2020) (65)
Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery. (2005) (64)
Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction: COMPLETE Trial. (2019) (64)
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. (2008) (63)
Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. (2009) (60)
Thrombus Aspiration in Patients With High Thrombus Burden in the TOTAL Trial. (2018) (60)
Precautions and Procedures for Coronary and Structural Cardiac Interventions During the COVID-19 Pandemic: Guidance from Canadian Association of Interventional Cardiology (2020) (57)
Stroke in Relation to Cardiac Procedures in Patients With Non–ST-Elevation Acute Coronary Syndrome: A Study Involving >18 000 Patients (2001) (57)
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. (2005) (56)
Impact of transradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes. (2011) (55)
Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-analysis. (2020) (55)
Radial versus femoral access for elderly patients with acute coronary syndrome undergoing coronary angiography and intervention: insights from the RIVAL trial. (2015) (51)
Incidence of thrombosis in perioperative and non‐operative myocardial infarction (2017) (50)
Sharing Data from Cardiovascular Clinical Trials--A Proposal. (2016) (50)
Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)‐5 trial (2010) (50)
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. (2001) (50)
Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. (2008) (49)
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. (2008) (48)
Reperfusion strategies in acute myocardial infarction and multivessel disease (2017) (47)
Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Study (2001) (47)
Ticagrelor with or without Aspirin in High-Risk Patients with Diabetes Mellitus undergoing Percutaneous Coronary Intervention. (2020) (47)
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial (2022) (46)
Design and rationale of the radial versus femoral access for coronary intervention (RIVAL) trial: a randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes. (2011) (45)
Nonculprit Lesion Plaque Morphology in Patients With ST-Segment–Elevation Myocardial Infarction (2020) (45)
Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 2: ST-segment elevation myocardial infarction. (2011) (44)
Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: The CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction☆ (2004) (44)
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. (2011) (44)
Association of cyclooxygenase-2 genetic variant with cardiovascular disease. (2014) (43)
Randomized Controlled Trial of Radiation Protection With a Patient Lead Shield and a Novel, Nonlead Surgical Cap for Operators Performing Coronary Angiography or Intervention (2015) (42)
Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. (2009) (40)
Ticagrelor With Aspirin or Alone After Complex PCI: The TWILIGHT-COMPLEX Analysis. (2020) (39)
Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 1: non-ST-segment elevation ACS. (2011) (37)
Rule-In and Rule-Out of Myocardial Infarction Using Cardiac Troponin and Glycemic Biomarkers in Patients with Symptoms Suggestive of Acute Coronary Syndrome. (2017) (36)
Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. (2009) (36)
Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents. (2019) (34)
Effect of PON1 Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (2012) (33)
Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. (2002) (32)
The risks of waiting for cardiac catheterization: a prospective study. (2002) (31)
Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department (2018) (30)
Effect of Body Mass Index on Clinical Events After Acute Coronary Syndromes. (2017) (28)
Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. (2017) (28)
Computed tomographic coronary angiographic assessment of high-risk coronary anatomy in patients with suspected coronary artery disease and intermediate pretest probability. (2008) (27)
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III). (2013) (27)
Timing of Angiography and Outcomes in High-Risk Patients With Non–ST-Segment–Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban) (2017) (26)
Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials: Intracranial hemorrhage in trials of bolus thrombolytic therapy. (2001) (26)
Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital (2018) (25)
Clinical outcomes and cost implications of routine early PCI after fibrinolysis: one-year follow-up of the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) study. (2013) (25)
First-in-Human Images of Coronary Atherosclerosis and Coronary Stents Using a Novel Hybrid Intravascular Ultrasound and Optical Coherence Tomographic Catheter. (2018) (24)
Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. (2005) (23)
Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. (2012) (23)
Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. (2016) (23)
Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial. (2007) (22)
High-Sensitivity Cardiac Troponin Risk Cutoffs for Acute Cardiac Outcomes at Emergency Department Presentation. (2017) (21)
Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure (2022) (21)
A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. (2006) (21)
Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience. (2009) (21)
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study (2019) (20)
Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy. (2016) (20)
Incremental Value of Left Ventricular Systolic and Diastolic Function to Determine Outcome in Patients with Acute ST‐Segment Elevation Myocardial Infarction: The Echocardiographic Substudy of the OASIS‐6 Trial (2014) (20)
The prognostic impact of revascularization strategy in acute myocardial infarction and cardiogenic shock: Insights from the British Columbia Cardiac Registry (2018) (19)
Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT). (2016) (18)
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. (2021) (18)
Aspirin for Prevention and Treatment of Cardiovascular Disease (2009) (17)
Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. (2005) (17)
Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with (2010) (17)
Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial. (2010) (16)
Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. (2021) (16)
Secretory Phospholipase A2-IIA and Cardiovascular Disease A Mendelian Randomization Study (2017) (16)
Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction. (2019) (16)
Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents (2020) (16)
Activated Clotting Time and Outcomes During Percutaneous Coronary Intervention for Non–ST-Segment–Elevation Myocardial Infarction: Insights From the FUTURA/OASIS-8 Trial (2015) (16)
Performance of high-sensitivity cardiac troponin in the emergency department for myocardial infarction and a composite cardiac outcome across different estimated glomerular filtration rates. (2018) (16)
Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin (2012) (15)
Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy. (2017) (15)
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. (2021) (15)
Multivessel Revascularization and ST-Segment-Elevation Myocardial Infarction: Do We Have the Complete Answer? (2017) (14)
Acute coronary syndromes without ST segment elevation (2007) (14)
Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. (2020) (13)
Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit (2011) (13)
A Prospective Evaluation of Sedative, Analgesic, Anti-Psychotic and Paralytic Practices in Canadian Mechanically Ventilated Adults. (2009) (13)
Economic Considerations of Early Rule-In/Rule-Out Algorithms for The Diagnosis of Myocardial Infarction in The Emergency Department Using Cardiac Troponin and Glycemic Biomarkers. (2017) (12)
Coronary intervention: radial artery access comes of age (2015) (12)
Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines. (2002) (12)
Warfarin after bioprosthetic aortic valve implantation. (2012) (11)
Clinical evaluation of Ortho Clinical Diagnostics high-sensitivity cardiac troponin I assay in patients with symptoms suggestive of acute coronary syndrome. (2020) (11)
A laboratory score at presentation to rule-out serious cardiac outcomes or death in patients presenting with symptoms suggestive of acute coronary syndrome. (2017) (11)
Providing optimal regional care for ST-segment elevation myocardial infarction: a prospective cohort study of patients in the Hamilton Niagara Haldimand Brant Local Health Integration Network. (2015) (11)
Double‐Dose Versus Standard‐Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (2017) (11)
Abstract 2654: Major Bleeding in Patients with Acute Coronary Syndrome Undergoing Early Invasive Management Can Be Reduced by Fondaparinux, Even in the Context of Trans-Radial Coronary Intervention: Insights from OASIS-5 Trial (2006) (11)
Nonculprit Vessel Intervention: Let's COMPLETE the Evidence. (2017) (11)
Comparison of Heart Team vs Interventional Cardiologist Recommendations for the Treatment of Patients With Multivessel Coronary Artery Disease (2020) (10)
Effects on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: Meta-Analysis of Individual Patient Data From 7 Multicenter Randomized Clinical Trials (2022) (10)
Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy. (2017) (10)
Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: a subgroup analysis from Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). (2012) (10)
Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. (2021) (9)
Comparison of the efficacy of pharmacoinvasive management for ST-segment elevation myocardial infarction in smokers versus non-smokers (from the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction). (2014) (9)
Antiplatelet Therapy and Coronary Artery Bypass Grafting: Analysis of Current Evidence With a Focus on Acute Coronary Syndrome. (2019) (9)
Cost implication of an early invasive strategy on weekdays and weekends in patients with acute coronary syndromes. (2015) (9)
Refining Antithrombotic Therapy for Atrial Fibrillation and Acute Coronary Syndromes or PCI. (2019) (9)
Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI (2018) (9)
Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI-CURE. (2003) (9)
Using the clinical chemistry score in the emergency department to detect adverse cardiac events: a diagnostic accuracy study. (2020) (9)
Antiplatelet therapy and coronary artery bypass grafting: a systematic review and network meta-analysis. (2020) (9)
Heparin use for diagnostic cardiac catheterization with a radial artery approach: An international survey of practice patterns (2018) (9)
Comparison of two biomarker only algorithms for early risk stratification in patients with suspected acute coronary syndrome. (2020) (9)
Risk of intracranial hemorrhage with bolus vs. infusion thrombolytic therapy: a meta-analysis (2001) (8)
Varying Effects of Body Mass Index and Mortality in Different Risk Groups. (2018) (8)
Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy (2020) (8)
A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. (2016) (8)
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. (2021) (8)
Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease (2021) (8)
Utility of Unfractionated Heparin in Transradial Cardiac Catheterization: A Systematic Review and Meta-analysis. (2017) (8)
A Multicentre Pilot Randomized Trial of High Frequency Oscillation in Acute Respiratory Distress Syndrome. (2009) (8)
A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. (2019) (7)
Duration of dual antiplatelet therapy and associated outcomes following percutaneous coronary intervention for acute myocardial infarction: contemporary practice insights from the Canadian Observational Antiplatelet Study (2016) (7)
The cost implications of an early versus delayed invasive strategy in acute coronary syndromes: the TIMACS study (2014) (7)
Canadian Stroke Best Practice Recommendations, seventh edition: acetylsalicylic acid for prevention of vascular events (2020) (7)
Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). (2017) (7)
Aspirin resistance and its implications in clinical practice. (2005) (7)
Clopidogrel in non-ST-segment elevation acute coronary syndromes (2006) (7)
Abstract 3294: Fondaparinux versus Control (Placebo or Unfractionated Heparin) as an Adjunct to Thrombolytic Therapy in Acute Myocardial Infarction: an OASIS 6 Substudy (2006) (7)
Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6 (2009) (6)
Long-term management of unstable angina and non-Q-wave myocardial infarction (2000) (6)
2387Recurrent cardiovascular events and mortality in relation to antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease (MINOCA) (2019) (6)
Clopidogrel in acute coronary syndromes: Where are we now? (2011) (6)
Routine Ultrasonography Guidance for Femoral Vascular Access for Cardiac Procedures: The UNIVERSAL Randomized Clinical Trial. (2022) (6)
Incremental cost-effectiveness of early and long-term clopidogrel in patients undergoing percutaneous coronary infarction in the CURE trial: The PCI-CURE economic analysis (2003) (6)
High-sensitivity cardiac troponin concentrations at emergency department presentation in females and males with an acute cardiac outcome (2018) (6)
Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI) (2006) (6)
Intracranial haemorrhage with bolus thrombolytic agents (2000) (6)
Primary Outcomes of the EVOLVE II Trial: A Prospective Randomized Investigation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent (2014) (6)
Smokers and Postcessation Weight Gain After Acute Coronary Syndrome (2017) (6)
1137-77 Long-term cost-effectiveness of clopidogrel in patients having percutaneous coronary intervention early after acute coronary syndrome: Results from PCI-CURE (2004) (6)
Safety and Efficacy of Ticagrelor Monotherapy According to Drug-Eluting Stent Type: The TWILIGHT-STENT Study. (2021) (5)
Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score. (2021) (5)
Clinical benefit and practical use of fondaparinux in the invasive management of patients with acute coronary syndromes (2008) (5)
Safety and efficacy of the bioabsorbable polymer everolimus‐eluting stent versus durable polymer drug‐eluting stents in high‐risk patients undergoing PCI: TWILIGHT‐SYNERGY (2020) (5)
Marital status and outcomes after myocardial infarction: Observations from the Canadian Observational Antiplatelet Study (COAPT) (2018) (5)
Complete Revascularization vs Culprit Lesion-Only Percutaneous Coronary Intervention for Angina-Related Quality of Life in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPLETE Randomized Clinical Trial. (2022) (5)
Complete Revascularization with Multivessel PCI for Myocardial Infarction. Reply. (2020) (5)
Activated Clotting Time to Guide Heparin Dosing in Non–ST-Segment–Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes Insights From the TAO Trial (2018) (4)
Adjudication Calibration for Pulmonary Embolism in a Thromboprophylaxis Trial. (2009) (4)
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI (2022) (4)
Identifying and Treating Young Patients at Risk for Cardiovascular Events. (2018) (4)
Antiplatelet therapy and coronary artery bypass grafting (2019) (4)
Right ventricular tachycardia: common presentation versus common disease. (2013) (4)
Persistent increases in cardiac troponin concentrations as measured with high-sensitivity assays after acute myocardial infarction. (2013) (4)
Short durations of radial hemostatic device post diagnostic transradial cardiac catheterization- The PRACTICAL-2 randomized trial. (2020) (4)
Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial. (2021) (4)
Acute Coronary Syndromes and Multivessel Disease: Completing the Evidence. (2020) (4)
Transcatheter Repair for Patients with Tricuspid Regurgitation. (2023) (3)
Effects of aspiration thrombectomy on mortality in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of the randomized trials. (2009) (3)
Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. (2020) (3)
Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy (2022) (3)
Complete revascularization in stable multivessel coronary artery disease: A real world analysis from the British Columbia Cardiac Registry (2021) (3)
Role of triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents (2010) (3)
COMPLETE VERSUS CULPRIT-LESION-ONLY REVASCULARIZATION FOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: A COLLABORATIVE META-ANALYSIS OF RANDOMIZED TRIALS (2020) (3)
Aspirin for Acute Coronary Syndromes: Have We Learned the Correct Dose Yet? (2010) (3)
META-ANALYSIS OF INTRACORONARY THROMBOLYTIC AS AN ADJUNCT TO PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (2015) (3)
Efficacy and safety of a routine early invasive strategy in relation to time from symptom onset to fibrinolysis (a subgroup analysis of TRANSFER-AMI). (2015) (3)
First in‐human evaluation of a novel intravascular ultrasound and optical coherence tomography system for intracoronary imaging (2021) (3)
INCIDENCE AND PREDICTORS OF NO REFLOW PHENOMENON: INSIGHTS FROM THE TOTAL TRIAL (2017) (3)
Efficacy and safety of a routine early invasive strategy after fibrinolysis stratified by glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: a pre-specified subgroup analysis of the TRANSFER-AMI randomised controlled trial (2014) (2)
Culprit-Only Versus Complete Coronary Revascularization After ST-Segment Elevation Myocardial Infarction- A Systematic Review and Analysis of Clinical Outcomes. (2019) (2)
FONDAPARINUX REDUCED MAJOR BLEEDING VERSUS ENOXAPARIN IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING EARLY INVASIVE MANAGEMENT EVEN IN THE CONTEXT OF TRANS-RADIAL CORONARY INTERVENTION: INSIGHTS FROM OASIS-5 (2007) (2)
Abstract 4585: Efficacy and Safety of Clopidogrel in Acute Coronary Syndrome Patients at High Risk of Bleeding: Data from the CURE Trial (2008) (2)
DUAL ANTIPLATELET THERAPY IN TYPE 1 AND TYPE 2 MYOCARDIAL INFARCTIONS: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDIES (2016) (2)
Cangrelor: a new CHAMPION for percutaneous coronary intervention (2013) (2)
Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial. (2022) (2)
MitraClip and Transcatheter Aortic Valve Replacement in a Patient With Recurrent Heart Failure. (2017) (2)
Matrix metalloproteinase inhibition reduces collagen synthesis and content after arterial injury (1996) (2)
Complete or Incomplete Revascularization for ST-Segment Elevation Myocardial Infarction: The PRAMI Trial to COMPLETE. (2020) (2)
Issues in the management of antiplatelet therapy in patients undergoing surgical revascularization. A roundtable discussion. (2005) (2)
Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insights from the TAO randomized clinical trial. (2020) (2)
How Should We Treat Multi-Vessel Disease in STEMI Patients? (2013) (2)
A randomized comparison of dalteparin versus unfractionated heparin during percutaneous coronary interventions (2003) (2)
Balancing thrombotic events and bleeding in primary PCI. (2013) (2)
PATTERNS OF ADP RECEPTOR INHIBITOR USE DURING THE INDEX HOSPITALIZATION IN PATIENTS WITH MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CANADIAN OBSERVATIONAL ANTIPLATELET STUDY (COAPT) (2014) (2)
Abstract 6178: Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) - Six Month Outcomes (2008) (2)
Impact of Transcatheter Mitral Valve Repair on Preprocedural and Postprocedural Hospitalization Rates. (2021) (2)
Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. (2021) (2)
SUSTAINED SMOKING ABSTINENCE 12 MONTHS AFTER ACUTE CORONARY SYNDROME: FOLLOW-UP FROM A RANDOMIZED CONTROLLED TRIAL OF VARENICLINE IN HOSPITALIZED PATIENTS (2016) (2)
An annual, prospective, international study of outpatients with cardiovascular disease or risk factors: design and methods of the CardioMonitor registry. (2007) (2)
Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada (2020) (2)
Glucose-Insulin-Potassium Therapy in Patients With STEMI—Reply (2008) (2)
The Evolution of Antiplatelet Therapy Following Percutaneous Coronary Interventions: a 40-Year Journey. (2022) (2)
Benefit of clopidogrel in patients undergoing percutaneous coronary intervention in the CURE trial receiving and not receiving an intracoronary stent (2003) (1)
Impact of provincial and national implementation strategies on P2Y12 inhibitor utilization for acute coronary syndrome in the elderly: an interrupted time series analysis from 2008 to 2018 (2021) (1)
P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists (2017) (1)
Design and Rationale of Routine UltrasouNd GuIdance for Vascular AccEss foR Cardiac Procedures: A Randomized TriaL (UNIVERSAL) (2022) (1)
Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. (2020) (1)
The Evolution of Anticoagulation for Percutaneous Coronary Intervention:A 40-Year Journey. (2022) (1)
Non-infarct related artery revascularization in ST-segment elevation myocardial infarction patients with multivessel disease (2017) (1)
Novel approaches to guide complete revascularisation in patients with STEMI and multivessel coronary artery disease. (2020) (1)
P5106Prevalence, clinical characteristics and outcomes of procedural complications of percutaneous coronary intervention in non ST-elevation myocardial infarction: insights from the TAO trial (2018) (1)
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. (2022) (1)
Cost–effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial (2022) (1)
MARITAL STATUS, LIVING ARRANGEMENT, AND OUTCOMES FOLLOWING MYOCARDIAL INFARCTION: OBSERVATIONS FROM THE CANADIAN OBSERVATIONAL ANTIPLATELET STUDY (COAPT) (2016) (1)
UTILITY OF UNFRACTIONATED HEPARIN IN TRANSRADIAL CARDIAC CATHETERIZATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED STUDIES (2017) (1)
Radial versus femoral access in acute coronary syndromes – Authors' reply (2011) (1)
Comparison of Dabigatran Plus a P2Y12 Inhibitor with Warfarin-Based Triple Therapy across Body Mass Index in RE-DUAL PCI. (2020) (1)
Nonculprit Lesion Intervention: 1 Step Closer to the COMPLETE Answer? (2018) (1)
Current High Frequency Oscillation (HFO) Utilization in Ontario. (2009) (1)
Balance of Benefit and Risk of Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease According to Bleeding Risk Assessment With the CRUSADE Score: Data From THEMIS and THEMIS PCI: Abbreviated title: Bleeding risk stratification of ticagrelor. (2022) (1)
TCT-145 RADIATION PROTECT: A randomized trial to assess the effectiveness of a novel pelvic lead shield and a novel, non-lead surgical cap to reduce operator radiation exposure during coronary angiography or intervention (2014) (1)
Anatomy vs. physiology: how should we achieve complete revascularization in acute coronary syndromes? (2023) (1)
Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment–Elevation Myocardial Infarction (2021) (1)
Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. (2021) (1)
Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease with a history of PCI: an economic evaluation of THEMIS-PCI using a Swedish healthcare perpective (2020) (1)
BLEEDING AND ISCHEMIC EVENTS IN CANADIAN PATIENTS WITH MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CANADIAN OBSERVATIONAL ANTIPLATELET STUDY (COAPT) AT 1 YEAR (2014) (1)
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. (2022) (1)
Abstract 3296: Effects of Fondaparinux in Patients with ST-Segment Elevation Acute Myocardial Infarction Non-Eligible for Reperfusion Treatment (2006) (1)
Effect of PON 1 Q 192 R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the CURE and ACTIVE Trials (2012) (1)
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. (2022) (1)
Double-dose clopidogrel in patients undergoing PCI for ACS – Authors' reply (2011) (1)
Future Prospects in the Management of Acute Coronary Syndrome and Thrombosis (2006) (0)
Abstract 16391: The Impact of Smoking on Clinical Outcomes and the Role of Double-Dose versus Standard-Dose Clopidogrel Among Individuals With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention - Insights From the CURRENT-OASIS 7 Trial (2016) (0)
Reply: Clarification of Methodology in the COMPLETE Timing Sub Study. (2020) (0)
Response to Letter Regarding Article, “Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction” (2010) (0)
Use patterns, clinical correlates and lesion characteristics of new devices demonstrate gender differences (1994) (0)
Percutaneous Coronary Intervention and Concomitant Antithrombotic Therapy (2011) (0)
RADIAL VERSUS FEMORAL ACCESS FOR CORONARY ANGIOGRAPHY/INTERVENTION IN WOMEN WITH ACUTE CORONARY SYNDROMES: INSIGHTS FROM THE RIVAL TRIAL (2014) (0)
CRT-100.01 Ultrasound-Guided Femoral Access in Patients With Vascular Closure Devices: Insights From the Randomized UNIVERSAL Trial (2023) (0)
COMPLETE revascularisation improves angina-related QoL (2022) (0)
1098-79 Renal function predicts outcomes in acute coronary syndromes: Insights from the CURE trial (2004) (0)
4Th International Summit on Atherothrombosis (2004) (0)
DURATION OF DUAL ANTIPLATELET THERAPY AND ASSOCIATED OUTCOMES FOLLOWING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE MYOCARDIAL INFARCTION: CONTEMPORARY PRACTICE INSIGHTS FROM THE CANADIAN OBSERVATIONAL ANTIPLATELET STUDY (COAPT) (2015) (0)
Chapter 5 – Aspirin and Thienopyridines (2004) (0)
COMPLETE REVASCULARIZATION IN PATIENTS UNDERGOING A PHARMACOINVASIVE STRATEGY FOR STEMI (2021) (0)
Effect of aspirin discontinuation according to individualised patient bleeding and ischemic risks after PCI: a TWILIGHT trial sub-analysis (2022) (0)
Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT) (2022) (0)
Fondaparinux in acute coronary syndromes (2008) (0)
Edinburgh Research Explorer Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (2017) (0)
Edinburgh Research Explorer Secretory Phospholipase A2-IIA and Cardiovascular Disease (2018) (0)
248 Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: A subgroup analysis from TRANSFER-AMI (2011) (0)
Timing of Intervention in Non-ST Elevation Acute Coronary Syndromes: What Is the VERDICT? (2018) (0)
Clinical Significance of Culprit Vessel Occlusion in Patients With Non-ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. (2023) (0)
Authors' reply to “Could radial instead of femoral access for coronary angiography change renal outcome? Nephrologists call for help” (2012) (0)
427 Providing a Platform for Organized Care in ST Elevation Myocardial Infarction: The LHIN-4 SMART-AMI Project in Southern Ontario Experience (2012) (0)
Abstract 17886: Impact of a Very Early Invasive Strategy in High Risk NSTEMI: Analysis From the TAO (Treatment for Acute Coronary Syndromes With Otamixaban) Trial (2016) (0)
TCT-487 Heart Failure in ST-Segment Elevation Myocardial Infarction, Predictors and Prognostic Impact: Insights From the TOTAL Trial (2019) (0)
THERAPEUTIC STRATEGY MULTIVESSEL DISEASE: WHAT WERE THEY THINKING? (2014) (0)
The relative safety and efficacy of clopidogrel in women and men: Meta-analysis of 79,613 patients enrolled in CREDO, CURE, CLARITY-TIMI 28, COMMIT, and CHARISMA (2007) (0)
EFFICACY AND SAFETY OF A ROUTINE EARLY INVASIVE STRATEGY IN RELATION TO TIME FROM SYMPTOM ONSET TO FIBRINOLYSIS: A SUBGROUP ANALYSIS FROM TRANSFER-AMI (2014) (0)
BETA BLOCKERS IN PATIENTS WITH ACUTE CORONARY SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS IN THE REPERFUSION ERA (2020) (0)
Enoxaparin versus Unfractionated Heparin in ST-Elevation Myocardial Infarction (2006) (0)
Response by Bagai et al to Letter Regarding Article, "Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention". (2016) (0)
SHORT DURATIONS OF COMPRESSION HEMOSTATIC DEVICE APPLICATION POST TRANS-RADIAL CARDIAC CATHETERIZATION: THE PRACTICAL-2 TRIAL (2020) (0)
Hirudin for Acute Coronary Syndromes (2002) (0)
Antiplatelet therapy prescription patterns for acute coronary syndrome: a decade analysed (2020) (0)
Blood pressure and clinical outcomes in patients with diabetes and stable coronary artery disease in THEMIS (2022) (0)
Efficacy and Safety of a Routine Pharmacoinvasive Strategy After Fibrinolysis Stratified by Glycoprotein IIB/IIIA Inhibitor Use: A Pre-Specified Subgroup Analysis of the Transfer-AMI Trial (2013) (0)
Abstract 5617: Paradoxical Low Use of Coronary Interventions in High-Risk Non-st Segment Acute Coronary Syndromes with Heart Failure. Data from the Oasis-5 Randomized Trial (2008) (0)
Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention (2022) (0)
Shock and Awe: Percutaneous Edge-to-Edge Repair of Post–Cardiac Surgery Severe Mitral Regurgitation Related to Papillary Muscle Tear (2021) (0)
Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes 1 (2005) (0)
Endometriosis-Associated Ovarian Carcinomas (2011) (0)
P ifferences in the Management nd Prognosis of Women and Men ho Suffer From Acute Coronary Syndromes (2016) (0)
The glycoprotein IIb/IIIa inhibitors in PCI: A record of success (2002) (0)
Abstract 3631: Elevated In-hospital Glucose Level, and not Known History of Diabetes Mellitus, Predicts 30-day Mortality Following Acute ST-elevation Myocardial Infarction (2007) (0)
Angiotensin Converting Enzyme Inhibitors/ Angiotensin Receptor Blockers and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization: Captain Trial (2013) (0)
CLOPIDOGREL VERSUS NOVEL P2Y12 INHIBITOR USE IN FIBRINOLYSIS TREATED ST SEGMENT ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE CANADIAN OBSERVATIONAL ANTIPLATELET STUDY (COAPT) (2016) (0)
SWITCHING AND PREMATURE DISCONTINUATION OF ADP RECEPTOR INHIBITOR THERAPY PRESCRIBED AT HOSPITAL DISCHARGE AMONG MYOCARDIAL INFARCTION PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CANADIAN OBSERVATIONAL ANTIPLATELET STUDY (COAPT) (2015) (0)
Achieving Complete Revascularization for Multivessel Coronary Artery Disease. (2021) (0)
Ticagrelor With or Without Aspirin in High-Risk Patients With Anemia Undergoing Percutaneous Coronary Intervention: a subgroup analysis of the TWILIGHT trial. (2023) (0)
PREVALENCE AND IMPACT OF ANGINA IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE AND DIABETES. INSIGHTS FROM THE THEMIS TRIAL (2023) (0)
Antiplatelet therapy: Aspirin. Discussion (2003) (0)
SYNERGY- EVEROLIMUS ELUTING STENT WITH A BIOABSORBABLE POLYMER IN ST ELEVATION MYOCARDIAL INFARCTION- CLEAR SYNERGY OASIS-9 TRIAL (2022) (0)
P2298High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCI (2018) (0)
IN-HOSPITAL AND LONG-TERM ISCHEMIC AND BLEEDING EVENTS IN PATIENTS WITH MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: FINAL RESULTS FROM THE CANADIAN OBSERVATIONAL ANTIPLATELET STUDY (COAPT) (2015) (0)
There was a strong association between increasing peak CK-MB fraction and increasing mortality among patients with ACS without ST-segment elevation (2000) (0)
Ultrasound-guided femoral access in patients with vascular closure devices: a prespecified analysis of the randomised UNIVERSAL trial. (2023) (0)
Coronary stenting reduced the rate of restenosis in patients with a first or subsequent restenosis (1999) (0)
P565Cardiac troponin T concentrations 30 days post myocardial infarction: Results of a small prospective observational study (2012) (0)
EFFICACY OF PHARMACOINVASIVE MANAGEMENT FOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN RELATION TO SMOKING STATUS: A SUBGROUP ANALYSIS OF TRANSFER-AMI (2014) (0)
Clopidogrel and percutaneous coronary intervention (2002) (0)
SAME-DAY DISCHARGE VERSUS USUAL CARE AFTER UNCOMPLICATED PERCUTANEOUS CORONARY INTERVENTION IN ELECTIVE AND LOW-RISK ACUTE CORONARY SYNDROME PATIENTS: A PROSPECTIVE AND RANDOMIZED TRIAL (2014) (0)
Efficacy of betablockers in patients with acute coronary syndrome: a systematic review and meta analysis of randomized trials (2020) (0)
ANTIPLATELET THERAPY PRESCRIPTION PRACTICES FOR ACUTE CORONARY SYNDROME: A DECADE ANALYZED (2020) (0)
More Attention Should Be Paid to Less Severe Nonculprit Lesions-Reply. (2023) (0)
FINAL 5-YEAR OUTCOMES OF THE EVOLVE II TRIAL: A PROSPECTIVE RANDOMIZED INVESTIGATION OF A NOVEL BIOABSORBABLE POLYMER-COATED, EVEROLIMUS-ELUTING SYNERGY STENT (2019) (0)
HEART FAILURE IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION, PREDICTORS AND PROGNOSTIC IMPACT: INSIGHTS FROM THE TOTAL TRIAL (2019) (0)
TICAGRELOR MONOTHERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN HIGH-RISK PATIENTS WITH OR WITHOUT HISTORY OF MYOCARDIAL INFARCTION. A PRESPECIFIED TWILIGHT SUBSTUDY (2021) (0)
TCT-236 Coronary Artery Bypass Grafting in Patients Presenting With ST-Segment Elevation Myocardial Infarction: The Optimal Timing and Impact on Outcomes: Insights From the TOTAL Trial (2019) (0)
P2Y12 Inhibitor Utilization for Acute Coronary Syndrome in the Elderly: A Provincial Analysis From 2008 to 2018 (2020) (0)
425 Complete Versus Culprit-Only Revascularization in ST Elevation Myocardial Infarction With Multi-Vessel Disease Undergoing Primary Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis (2012) (0)
403-P: Impact of Diabetes-Related Factors and Background Antihyperglycemic Therapy on the Efficacy and Safety of Ticagrelor Added to Aspirin: Insights from the THEMIS Trial (2020) (0)
EFFECTS OF BASELINE PLATELET REACTIVITY IN FIBRINOLYSIS-TREATED ST ELEVATION MYOCARDIAL INFARCTION PATIENTS UNDERGOING EARLY PERCUTANEOUS CORONARY INTERVENTION (2018) (0)
P5537Clinical outcomes, mortality, and causes of death in patients with NSTEMI according to heart failure at admission: insights from a large contemporary revascularization trial (2018) (0)
ADP RECEPTOR INHIBITOR USE AND SWITCHING IN PATIENTS WITH MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CANADIAN OBSERVATIONAL ANTIPLATELET STUDY (COAPT) (2015) (0)
TCT-217 Predictors of Dyspnea in Patients Receiving Ticagrelor After PCI: Insights From the Twilight Trial (2021) (0)
Dual Antiplatelet Patterns in Patients With Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Prospective Canadian Observational Antiplatelet Study (COAPT) (2013) (0)
Platelets in Thrombotic and Non-thrombotic Disorders: Design of trials to evaluate antiplatelet agents (2002) (0)
A review of recent anti-thrombotic clinical trials (2006) (0)
ISCHEMIC AND BLEEDING EVENTS IN CANADIAN PATIENTS WITH MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WHO REQUIRE ORAL ANTICOAGULATION: INSIGHTS FROM THE CANADIAN OBSERVATIONAL ANTIPLATELET STUDY (COAPT) (2015) (0)
After PCI with stents for AF, adding rivaroxaban vs warfarin to antiplatelet drugs reduced bleeding (2017) (0)
Erratum to: Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin (2012) (0)
External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry. (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Shamir R. Mehta?

Shamir R. Mehta is affiliated with the following schools:

McGill University
McMaster University
Columbia University

Shamir R. Mehta's Academic­Influence.com Rankings

Shamir R. Mehta's Degrees

Why Is Shamir R. Mehta Influential?

Shamir R. Mehta's Published Works

Published Works

What Schools Are Affiliated With Shamir R. Mehta?

Shamir R. Mehta's AcademicInfluence.com Rankings